Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 5/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204881 | 0.82 | ALOX5AP (0.35) | FEN1ALOX5APHTR2AHTR2CHTR2B | |
| SCHEMBL20201618 | 0.82 | ALOX5AP (0.36) | FEN1ALOX5APDRD2DRD3HTR2C | |
| SCHEMBL21325347 | 0.79 | RIPK1 (0.34) | FEN1ALOX5APHTR2AHTR2CHTR2B | |
| SCHEMBL21325053 | 0.79 | RIPK1 (0.34) | FEN1ALOX5APHTR2AHTR2CHTR2B | |
| SCHEMBL20206761 | 0.77 | FEN1 (0.36) | FEN1ALOX5APHTR2AHTR2CHTR2B | |
| SCHEMBL20376466 | 0.77 | FEN1 (0.36) | FEN1ALOX5APHTR2AHTR2CHTR2B | |
| SCHEMBL21533978 | 0.77 | FEN1 (0.37) | FEN1ALOX5AP | |
| SCHEMBL31674209 | 0.76 | ACHE (0.35) | DRD2DRD3ACHECYP11B1CYP11B2 | |
| SCHEMBL21325048 | 0.74 | ALOX5AP (0.34) | FEN1ALOX5APHTR2AHTR2CHTR2B | |
| SCHEMBL21325344 | 0.74 | ALOX5AP (0.34) | FEN1ALOX5APHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| WO-2018098206-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | S1PR1 3297/4885FEN1 108/4885ALOX5AP 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.